Dilip Kodira - PureTech Health Head Science
| PRTC Stock | USD 22.55 0.77 3.54% |
Executive
Dilip Kodira is Head Science of PureTech Health PLC
| Address | 6 Tide Street, Boston, MA, United States, 02210 |
| Phone | 617 482 2333 |
| Web | https://www.puretechhealth.com |
PureTech Health Management Efficiency
The company has return on total asset (ROA) of (0.1339) % which means that it has lost $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2207) %, meaning that it created substantial loss on money invested by shareholders. PureTech Health's management efficiency ratios could be used to measure how well PureTech Health manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.1. The current year's Return On Capital Employed is expected to grow to -0.22. As of November 22, 2024, Total Assets is expected to decline to about 544.9 M. In addition to that, Non Current Assets Total is expected to decline to about 257.8 MSimilar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kenneth Sall | Opthea | N/A | |
| PharmD MS | Opthea | 52 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| CPA CFA | Janux Therapeutics | 48 | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| Daron Evans | Rezolute | 50 | |
| MD MBA | Molecular Partners AG | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Karin Heidemann | Champions Oncology | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| MS MBA | Rezolute | 50 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Gopal MBBS | Rezolute | N/A | |
| Maria Dobek | Janux Therapeutics | 35 | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Michael Deperro | Rezolute | N/A | |
| Moses Makunje | Nuvation Bio | 45 | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 |
PureTech Health PLC Leadership Team
Elected by the shareholders, the PureTech Health's board of directors comprises two types of representatives: PureTech Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PureTech. The board's role is to monitor PureTech Health's management team and ensure that shareholders' interests are well served. PureTech Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PureTech Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anita JD, Senior Property | ||
| Lauren MBA, Chief Officer | ||
| David Elmaleh, CoFounder Advisor | ||
| Eric Elenko, CoFounder President | ||
| Spencer Ball, Senior Resources | ||
| III JD, General Secretary | ||
| Joseph Bolen, Chief Officer | ||
| Aleksandra MD, Head Oncology | ||
| Daphne Zohar, Senior Founder | ||
| Eric MBA, Chief Officer | ||
| Dilip Kodira, Head Science | ||
| Allison Talbot, Head Relations | ||
| Dr Langer, CoFounder Director | ||
| Bennett MD, CoFounder Advisor | ||
| Cheryl Murphy, Head Strategy | ||
| Dr JD, Secretary, President |
PureTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PureTech Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (230.55) % | ||||
| Current Valuation | 12.15 M | ||||
| Shares Outstanding | 23.94 M | ||||
| Shares Owned By Institutions | 0.12 % | ||||
| Number Of Shares Shorted | 6.28 K | ||||
| Price To Book | 1.65 X | ||||
| Price To Sales | 1,114 X | ||||
| Revenue | 3.33 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PureTech Health PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PureTech Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puretech Health Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puretech Health Plc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PureTech Health PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PureTech Health. If investors know PureTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PureTech Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.615 | Earnings Share (3.00) | Revenue Per Share 0.02 | Quarterly Revenue Growth (0.91) | Return On Assets (0.13) |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PureTech Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if PureTech Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PureTech Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.